S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
NASDAQ:TRDA

Entrada Therapeutics - TRDA Stock Forecast, Price & News

$18.90
-2.10 (-10.00%)
(As of 12/9/2022 01:23 PM ET)
Add
Compare
Today's Range
$18.70
$20.23
50-Day Range
$13.90
$22.79
52-Week Range
$5.12
$24.38
Volume
2,577 shs
Average Volume
47,811 shs
Market Capitalization
$593.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Entrada Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
4.8% Downside
$18.00 Price Target
Short Interest
Bearish
6.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Entrada Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$895,818 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.08) to ($3.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.95 out of 5 stars

Medical Sector

1013th out of 1,022 stocks

Pharmaceutical Preparations Industry

494th out of 499 stocks

TRDA stock logo

About Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRDA Stock News Headlines

Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics Inc (TRDA)
See More Headlines
Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRDA Company Calendar

Last Earnings
11/07/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRDA
Fax
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
-4.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-51,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.57 per share

Miscellaneous

Free Float
29,138,000
Market Cap
$593.65 million
Optionable
Not Optionable
Beta
-0.95

Key Executives

  • Mr. Dipal Doshi (Age 46)
    Pres, CEO & Director
    Comp: $788.11k
  • Mr. Nathan J. Dowden (Age 51)
    Chief Operating Officer
    Comp: $605.45k
  • Dr. Natarajan Sethuraman Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $621.87k
  • Mr. Kory James Wentworth CPA (Age 42)
    CFO & Treasurer
  • Dr. Jared Cohen J.D.
    Ph.D., Gen. Counsel
  • Ms. Kerry Robert M.S.
    VP of People
  • Dr. Nerissa C. Kreher M.B.A. (Age 49)
    M.D., M.S., Chief Medical Officer
  • Ms. Karla MacDonald
    Chief Corp. Affairs Officer













TRDA Stock - Frequently Asked Questions

Should I buy or sell Entrada Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRDA shares.
View TRDA analyst ratings
or view top-rated stocks.

What is Entrada Therapeutics' stock price forecast for 2023?

2 analysts have issued 1 year price targets for Entrada Therapeutics' stock. Their TRDA share price forecasts range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests that the stock has a possible downside of 6.3%.
View analysts price targets for TRDA
or view top-rated stocks among Wall Street analysts.

How have TRDA shares performed in 2022?

Entrada Therapeutics' stock was trading at $17.12 at the beginning of 2022. Since then, TRDA stock has increased by 12.2% and is now trading at $19.21.
View the best growth stocks for 2022 here
.

When is Entrada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our TRDA earnings forecast
.

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Monday, November, 7th. The company reported ($0.80) EPS for the quarter.

When did Entrada Therapeutics IPO?

(TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share.

What is Entrada Therapeutics' stock symbol?

Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA."

Who are Entrada Therapeutics' major shareholders?

Entrada Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.46%), Vanguard Group Inc. (2.77%), TCG Crossover Management LLC (2.04%), Laurion Capital Management LP (0.63%), BlackRock Inc. (0.47%) and Nan Fung Group Holdings Ltd (0.45%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Nathan J Dowden and Nerissa Kreher.
View institutional ownership trends
.

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entrada Therapeutics' stock price today?

One share of TRDA stock can currently be purchased for approximately $19.21.

How much money does Entrada Therapeutics make?

Entrada Therapeutics (NASDAQ:TRDA) has a market capitalization of $603.39 million. The company earns $-51,160,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Entrada Therapeutics have?

The company employs 114 workers across the globe.

How can I contact Entrada Therapeutics?

The official website for the company is www.entradatx.com. The company can be reached via phone at 857-520-9158 or via email at investors@entradatx.com.

This page (NASDAQ:TRDA) was last updated on 12/9/2022 by MarketBeat.com Staff